End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
137,000 KRW | -2.91% | -0.22% | -43.15% |
03-21 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-05 | South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's enterprise value to sales, at 3660.34 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.15% | 673M | D | ||
-2.35% | 89.08B | A- | ||
+3.55% | 40.9B | A- | ||
-13.51% | 32.25B | B- | ||
+54.25% | 25.14B | A | ||
-15.55% | 15.39B | C | ||
-8.20% | 11.91B | B- | ||
-41.29% | 11.89B | B | ||
-11.75% | 11.64B | D+ | ||
+6.82% | 9.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A086900 Stock
- Ratings Medy-Tox Inc.